|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We searched and evaluated all primary literature on the use of IHC for evaluating BRCA1 and BRCA2 proteins expression in EOC.
|
31719105 |
2020 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The clinicopathological parameters of 36 EOC patients carrying germline BRCA1/2 DM were compared to high-grade serous EOC women of the COEUR cohort with known germline BRCA1/BRCA2 mutation carrier status (n = 376 non-carriers, n = 65 BRCA1 and n = 38 BRCA2).
|
31753525 |
2020 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These genes are associated with an estimated lifetime risk of EOC of 13% to 60% for BRCA1 variants and 10% to 25% for BRCA2 variants, with lower risks associated with remaining genes.
|
31099061 |
2020 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor BRCA1/2 testing was performed for 315 (77.6%) of the 406 eligible OC samples, of which 305 (96.8%) were successful.
|
31076742 |
2020 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).
|
31797087 |
2020 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases.
|
30683677 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain.
|
30617925 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Epithelial ovarian cancer is composed of distinct histological subtypes with unique genomic characteristics, which are improving the precision and effectiveness of therapy, allowing discovery of predictors of response such as mutations in breast cancer susceptibility genes BRCA1 and BRCA2, and homologous recombination deficiency for DNA damage response pathway inhibitors or resistance (cyclin E1).
|
30910306 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
|
30872026 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A noteworthy example is treatment of TNBC and epithelial ovarian cancer harboring BRCA1/2 germline mutations using platinum salts and/or PARP inhibitors.
|
30661659 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Factors that predicted for BRCA1/2 mutations were: breast and ovarian cancers in the same patient (p = 0.031), young age of EOC (p = 0.029), menstrual status (p = 0.004) and family history of cancer (p < 0.0001).
|
30651582 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East.
|
30825404 |
2019 |
|
Epithelial ovarian cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, somatic or germinal mutations on BRCA1 and BRCA2 genes are the most important biomarkers in epithelial ovarian cancer having prognostic and predictive value.
|
28815456 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Areas covered: This review focuses on the rationale for olaparib therapy in the context of relapsed epithelial ovarian cancer associated with a BRCA1 or BRCA2 mutation and summarizes the existing efficacy and safety data in this context.
|
30092674 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
qPCR was used to investigate telomerase splice variants, MCPH1/BRIT1 and BRCA1 expression in EOC tissue and primary cultures.
|
29860064 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The cancer tissue specimens were divided into the chemotherapy resistance group and sensitivity group through the <i>in vitro</i> resin droplet experiment to analyze the association of the expression of HMGB1, BRCA1 and P62 in epithelial ovarian cancer with chemotherapy resistance of patients.
|
29844838 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.
|
30504414 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline sequence and large rearrangements for BRCA1/2 were tested in 398 consecutive epithelial ovarian cancer (EOC) patients.
|
30103829 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The study aimed to estimate risks of invasive BC and EOC in a large cohort of BRCA1/BRCA2 predictive test negatives.
|
29565421 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Approximately 10-15% of patients with EOC harbor a genetic predisposition due to mutations in BRCA1/2 genes.
|
29856239 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Germline BRCA1 or BRCA2 mutations (mtBRCA1 and mtBRCA2) increase risk for high-grade serous ovarian cancer (HGSOC), the most commonly diagnosed epithelial ovarian cancer histotype.
|
29852322 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2.
|
29020732 |
2018 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A decision model was developed to compare costs and outcomes of two testing strategies for women with EOC: multigene testing (MGT) versus single-gene testing for BRCA1/2.
|
28045615 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Owing to the rapid increase in clinical need, we aimed to implement and review the performance of a mainstreaming model of germline BRCA1/2 genetic testing in eligible women with high grade non-mucinous epithelial ovarian cancer via a Genetic Counselor embedded in the gynecology oncology clinic.
|
28162234 |
2017 |
|
Epithelial ovarian cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in BRCA1 and BRCA2 account for hereditary breast and ovarian cancer syndrome in a majority of families and 14% of epithelial ovarian cancer cases.
|
28254144 |
2017 |